Fund Profile
International Biotechnology 25 September 2017
A new version of this profile is available.
View Latest
Kepler Trust Intelligence provides research and information for professional and private investors. In order to ensure that we provide you with the right kind of content, and to ensure that the content we provide is compliant, you need to tell us what type of investor you are.
Read the full articleFund History
29 Apr 2022
Five trusts to diversify your portfolio income
Join us next month for one live webinar with a different manager every day of the week – including the chance to ask questions - focused on different solutions for those seeking a decent income…
14 Apr 2022
The inevitabilities: death and taxes
Biotech has had a rough ride lately but, as the world gets older and richer, our analysts think long-term secular growth is inevitable…
30 Mar 2022
You say tomato…
Do it yourself or put it into a global fund and leave it to the experts - our analyst debate the merits of each approach...
30 Mar 2022
Fund Analysis
IBT’s managers appear confident that valuations are increasingly attractive…
08 Dec 2021
Further cancer breakthroughs hinge on biotech investment
By Marek Poszepczynski and Ailsa Craig, co-investment managers of the International Biotechnology Trust...
13 Oct 2021
Fund Analysis
IBT remains differentiated to peers, offering exposure to the explosive potential of innovation in healthcare...
28 Jul 2021
How are the mighty fallen
Dividend culture as we knew it is dead, according to Kepler's David Johnson, but investment trusts offer a solution...
20 May 2021
Fund Analysis
IBT has had a change of management - but no change of strategy…
07 Apr 2021
Paging Dr Alpha
The pandemic has boosted secular growth drivers behind healthcare as an investment theme...
10 Mar 2021
Spring Conference '21
Audio and presentations from 21 of the UK’s leading investment trust managers…
08 Mar 2021
Slides and Audio: International Biotechnology Trust
Download the presentation and listen to the audio from our 'Ideas for your ISA' Spring Conference on 03 March...
04 Jan 2021
Fund Analysis
IBT offers a differentiated way to access strong growth prospects at an undemanding valuation...
01 Oct 2020
Alternatives for Income Investors
Slides and audio from our event focused on alternative routes to a reliable income…
30 Sep 2020
Slides and Audio: International Biotechnology
View the presentation and listen to the audio from our 'Alternatives for Income Investors' event on 29 September...
26 Aug 2020
Trump v. Biden
Two of our analysts debate who will win the US election and what that means for markets…
20 Aug 2020
Alternatives for income investors
In a world where dividend are under unprecedented pressure, our income focused online event in September should provide serious food for thought…
09 Jul 2020
The next big thing: two mega-trends that everyone should own
Tech has beaten almost everything hands down – but nothing lasts forever. Where else should investors be looking for secular growth themes?
08 Jul 2020
Fund Analysis
IBT offers a differentiated exposure to a secular growth theme complemented by a solid yield…
25 Jun 2020
Selling the family silver
Is there something fishy about a trust paying dividends from capital?
27 Feb 2020
Robbing Peter to pay Paul?
Two of our analysts discuss the growing trend for companies to pay an income out of capital…
12 Dec 2019
Fund Analysis
A highly experienced management team and a flexible portfolio of quoted and unquoted biotechnology stocks, with a yield target of 4% of NAV...
29 May 2019
Fund Analysis
We discuss the opportunity as biotech stocks trade at record low valuations, despite strong prospects for the sector...
03 May 2019
A steady hand
Chairman of International Biotechnology Trust, John Aston, explains how his unusual background in both biotechnology and banking come together on the trust...
15 Apr 2019
Art meets science
Carl Harald Janson explains how his experiences in science and business blend seamlessly in his management of International Biotechnology Trust...
06 Feb 2019
Income for the long haul
With 'ISA season' looming we identify investment trusts which offer long-term, dependable income streams for yield-hungry investors...
31 Oct 2018
The Trump effect
Two years after the shock election of Donald Trump, we take a look at what the Trump administration has really meant for US markets and the trusts that invest in them...
10 Oct 2018
Fund Analysis
Five years on from the appointment of a new manager, this US-focused biotech trust has seen its fortunes transformed...
22 Aug 2018
Reassuringly expensive?
Some investment trust premiums have been stretched to eye-watering levels. Have investors been enjoying themselves in the sun too much? We try to rationalise current levels and suggest alternatives...
22 Mar 2018
Fund Analysis
A well-resourced biotechnology fund that has produced annualised returns of +18% under the current manager, offering a yield of 4%...
22 Mar 2018
The search for discounted yield
We scour the investment trust universe for trusts offering chunky yields on a discount...
09 Jan 2018
The Income Diversifiers Conference
CPD certificate, speaker presentations and slides...
27 Sep 2017
Winners and losers from tomorrow’s world
Searching for the Tesla of tomorrow…
27 Sep 2017
Not the usual suspects...
As equity valuations continue to defy logic, we identify the trusts least correlated to their fortunes...
25 Sep 2017
Fund Analysis
Proven alpha generation from a strong management team, low correlation to mainstream equities, and a yield of 4%...
08 Jun 2017
The doctor will see you now...
Carl Harald Janson, once dubbed 'the world's best biotech manager' by Bloomberg, tells us what he thinks lies in store for the sector...
21 Feb 2017
Don't wanna be an American idiot
We highlight various routes to US exposure for those who are not sure how much faith they place in the 'Trump Bump'...
17 Nov 2016
Fund Analysis
16 Nov 2016
Fortune favours the brave
Our analysis shows that technology trusts are far less risky than the returns they have generated suggest...